

CLAIMS

This listing of claims will replace prior versions and listings of claims in the application:

1-8. (Cancelled).

9. (Currently amended) A method ~~for reducing restenosis in a patient having suffered a vascular injury, which comprises the step of reducing restenosis in a patient having suffered a vascular injury comprising by~~ administering a single dose unit of 1 to 5000 $\mu\text{g}/\text{Kg}$ of patient's body weight ~~an effective dose of 17- β estradiol or a derivative thereof with a device~~ at an injured site in the lumen of a blood vessel of said patient.

10. (Previously presented) The method of claim 9, wherein said dose is administered in a pharmaceutically acceptable carrier.

11-15. (Cancelled).

16. (Currently amended) A The method as defined in of claim 9, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 10 to 50 $\mu\text{g}/\text{Kg}$ of patient's body weight.

17. (Currently amended) A The method as defined in of claim 9, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 10 to 30 $\mu\text{g}/\text{Kg}$ of patient's body weight.

18-19. (Cancelled)

20. (Currently amended) A The method as defined in of claim 19 9, wherein the device is a catheter containing said 17- β estradiol or derivative thereof, and a pharmaceutically acceptable carrier.

21. (Currently amended) A The method as defined in of claim 19 9, wherein the device is a stent coated with said 17- β estradiol or derivative thereof, and a pharmaceutically acceptable carrier.

22. (Currently amended) A The method as defined in of claim 9, wherein said 17- β estradiol or derivative thereof is administered following percutaneous transluminal coronary angioplasty (PTCA).

23. (Currently amended) A The method as defined in of claim 9, wherein said 17- β estradiol or derivative thereof is administered simultaneously to percutaneous transluminal coronary angioplasty (PTCA).

24. (Currently amended) A The method as defined in of claim 9, wherein said method administers an effective dose of uses 17- β estradiol.

25. (Cancelled).

26. (Currently amended) A The method as defined in of claim 24, wherein 17- β estradiol is present in a dose unit of 10 to 50 $\mu\text{g}/\text{Kg}$ of patient's body weight.

27. (Currently amended) A The method as defined in of claim 24, wherein 17- β estradiol is present in a dose unit of 10 to 30 $\mu\text{g}/\text{Kg}$ of patient's body weight.

28-29. (Cancelled)

30. (Currently amended) A The method as defined in of claim 29 24, wherein the device is a catheter containing said 17- β estradiol, and a pharmaceutically acceptable carrier.

31. (Currently amended) A The method as defined in of claim 29 24, wherein the device is a stent coated with said 17- β estradiol, and a pharmaceutically acceptable carrier.

32. (Currently amended) A The method as defined in of claim 24, wherein said 17- β estradiol is administered following percutaneous transluminal coronary angioplasty (PTCA).

33. (Currently amended) A The method as defined in of claim 24, wherein said 17- β estradiol is administered simultaneously to percutaneous transluminal coronary angioplasty (PTCA).

34. (New) A device for local intracoronary delivery comprising 17- β estradiol or a derivative thereof in a dosage of 1 to 5000 $\mu\text{g}/\text{Kg}$ of patient's body weight, and a pharmaceutically acceptable parenteral vehicle.

35. (New) The device as defined in claim 34, wherein said device is a catheter.

36. (New) The device as defined in claim 34, wherein said device is a stent coated with said 17- β estradiol and said pharmaceutically acceptable parenteral vehicle.

37. (New) The device as defined in claim 34, wherein 17- β estradiol is in a dosage of 10 to 50 $\mu\text{g}/\text{Kg}$ of patient's body weight.

38. (New) The device as defined in claim 37, wherein 17- β estradiol is in a dosage of 10 to 30 $\mu\text{g}/\text{Kg}$ of patient's body weight.